Myovant Sciences Ltd (NYSE:MYOV) has earned a consensus rating of “Buy” from the nine research firms that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $29.67.

Several research firms have weighed in on MYOV. Zacks Investment Research upgraded shares of Myovant Sciences from a “hold” rating to a “buy” rating and set a $22.00 target price for the company in a research note on Thursday, April 18th. ValuEngine lowered shares of Myovant Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, April 13th. Barclays upgraded shares of Myovant Sciences from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $22.00 to $25.00 in a research note on Wednesday, February 13th. Evercore ISI began coverage on shares of Myovant Sciences in a research note on Thursday, April 11th. They set an “outperform” rating for the company. Finally, JMP Securities reiterated a “buy” rating and set a $25.00 target price on shares of Myovant Sciences in a research note on Monday, February 11th.

A number of hedge funds have recently added to or reduced their stakes in the business. RA Capital Management LLC increased its stake in Myovant Sciences by 7.5% during the fourth quarter. RA Capital Management LLC now owns 3,711,549 shares of the company’s stock valued at $60,907,000 after purchasing an additional 259,690 shares during the last quarter. BB Biotech AG boosted its holdings in shares of Myovant Sciences by 0.8% during the fourth quarter. BB Biotech AG now owns 3,597,882 shares of the company’s stock valued at $59,041,000 after acquiring an additional 30,000 shares during the period. Lord Abbett & CO. LLC boosted its holdings in shares of Myovant Sciences by 0.9% during the fourth quarter. Lord Abbett & CO. LLC now owns 1,913,548 shares of the company’s stock valued at $31,401,000 after acquiring an additional 16,668 shares during the period. Victory Capital Management Inc. acquired a new position in shares of Myovant Sciences during the first quarter valued at $20,104,000. Finally, Norges Bank acquired a new position in shares of Myovant Sciences during the fourth quarter valued at $12,308,000. Hedge funds and other institutional investors own 30.98% of the company’s stock.

MYOV stock traded down $0.33 during trading on Friday, hitting $12.48. 203,000 shares of the company’s stock traded hands, compared to its average volume of 108,488. The company has a debt-to-equity ratio of 2.08, a current ratio of 3.51 and a quick ratio of 3.51. Myovant Sciences has a 52 week low of $11.65 and a 52 week high of $27.45. The firm has a market cap of $956.68 million, a price-to-earnings ratio of -5.18 and a beta of 0.50.

About Myovant Sciences

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Further Reading: Differences Between Momentum Investing and Long Term Investing

Analyst Recommendations for Myovant Sciences (NYSE:MYOV)

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.